您当前所在的位置:首页 > 产品中心 > 产品信息
Tenofovir_分子结构_CAS_147127-20-6)
点击图片或这里关闭

Tenofovir

产品号 DB00300 公司名称 DrugBank
CAS号 147127-20-6 公司网站 http://www.ualberta.ca/
分子式 C9H14N5O4P 电 话 (780) 492-3111
分子量 287.212321 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 185

产品价格信息

请登录

产品别名

标题
Tenofovir
IUPAC标准名
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
IUPAC传统名
tenofovir
商标名
Apropovir
Viread
别名
PMPA
D,L-Tenofovir
Tenofovir disoproxil
TDF
Tenofovir disoproxil fumarate

产品登记号

PubChem CID 464205
CAS号 147127-20-6
PubChem SID 46508131

产品性质

疏水性(logP) -1.6
溶解度 13.4 mg/mL in distilled water at 25oC (disoproxil fumarate salt)

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Tenofovir, marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia]
Indication For use, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.
Pharmacology Tenofovir belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Tenofovir is currently in late-stage clinical trials for the treatment of hepatitis B. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Toxicity Limited clinical experience at doses higher than the therapeutic dose of tenofovir 300 mg is available. In Study 901 tenofovir disoproxil fumarate 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.
Affected Organisms
Human Immunodeficiency Virus
Biotransformation Neither tenofovir disoproxil nor tenofovir are substrates of CYP450 enzymes.
Absorption The oral bioavailability in fasted patients is approximately 25%. Administration of food (high fat meal containing 40 to 50% fat) increases the oral bioavailability, with an increase in the AUC of approximately 40%.
Half Life Approximately 17 hours.
Protein Binding Very low: < 0.7% to human plasma proteins and < 7.2% to serum proteins
Distribution * 1.3 ± 0.6 L/kg [tenofovir 1.0 mg/kg]
* 1.2 ± 0.4 L/kg [tenofovir 3.0 mg/kg]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献